Does Blue Cross Blue Shield of Alabama Cover Lantus?

What Is Lantus and Why Does Formulary Placement Matter?

Lantus is the brand name for insulin glargine 100 units/mL, a long-acting basal insulin manufactured by Sanofi. It lowers fasting blood glucose by providing a steady, peakless 24-hour insulin release. The FDA originally approved Lantus in April 2000, and it remains one of the most prescribed basal insulins in the United States. Where an insurer places a drug on its formulary directly determines what you pay per fill.

How Formulary Tiers Work

Most BCBS Alabama plans use a 4- to 6-tier formulary. Generic drugs sit on Tier 1 with the lowest copays, usually $0 to $15. Preferred brand-name drugs occupy Tier 2 at roughly $30 to $60. Non-preferred brands land on Tier 3 at $60 to $120 or more. Specialty drugs go even higher.

Because insulin glargine now has FDA-approved biosimilars, Lantus (the originator brand) has been repositioned on many commercial formularies. BCBS Alabama plans tend to favor biosimilar versions of insulin glargine on Tier 2 while placing Lantus on Tier 3, meaning a patient who specifically requests Lantus by name may pay $40 to $80 more per fill than a patient who accepts Basaglar or Semglee.

Clinical Equivalence of Insulin Glargine Products

The FDA defines biosimilar insulins as having no clinically meaningful differences from the reference product in terms of safety, purity, and potency. A 2018 randomized trial published in Diabetes Care (N=536) found Basaglar (insulin glargine-aabc) produced HbA1c reductions and hypoglycemia rates statistically equivalent to Lantus over 52 weeks 1. Semglee received interchangeable biosimilar status from the FDA in July 2021, the first insulin to do so, meaning pharmacists can substitute it for Lantus without a new prescription 2.

This regulatory equivalence is why BCBS Alabama, like most large insurers, uses formulary design to steer patients toward biosimilar products rather than the originator brand.

Does BCBS Alabama Require Prior Authorization for Lantus?

Prior authorization (PA) is required for Lantus on the majority of BCBS Alabama commercial, individual marketplace, and Medicare Advantage plans. The insurer asks the prescribing physician to submit clinical documentation before the plan will cover the drug at the in-network benefit level.

Typical PA Criteria for Lantus

BCBS Alabama PA criteria for insulin glargine (originator brand) generally include:

• Diagnosis of Type 1 or Type 2 diabetes with documented HbA1c above 7.0% or fasting glucose above 126 mg/dL 3
• Documentation that the patient has tried and failed, or cannot tolerate, at least one preferred-tier biosimilar insulin glargine product
• A prescriber attestation that switching to a biosimilar is clinically inappropriate, sometimes called a "medical necessity exception"

The American Diabetes Association's Standards of Care in Diabetes 2024 states that "insulin regimens should be designed to match the pharmacokinetic and pharmacodynamic profiles available to the patient given cost and access constraints" 4. This language gives prescribers a legitimate clinical basis to argue that a patient who has been stable on Lantus for years should not be switched purely for formulary reasons.

How Long PA Approvals Last

Standard BCBS Alabama PA approvals for Lantus run 12 months, after which the prescriber must resubmit. Urgent reviews are typically completed within 72 hours. Routine reviews take up to 15 calendar days under Alabama insurance regulations. Your pharmacy will notify you if a claim is pending PA rather than simply denying it at the point of sale.

How Much Will Lantus Cost Under BCBS Alabama?

Out-of-pocket cost depends on your specific plan, whether you have met your deductible, and whether Lantus is approved at the preferred or non-preferred tier.

Before Your Deductible Is Met

On high-deductible health plans (HDHPs) common in Alabama's ACA marketplace, you pay the negotiated rate for Lantus until the deductible is satisfied. Negotiated rates between BCBS Alabama and pharmacy benefit managers typically fall between $120 and $220 per 10 mL vial, which is well below the $292 to $396 list price but still substantial.

After Your Deductible Is Met

Once the deductible clears, Tier 3 copays for Lantus on standard BCBS Alabama commercial plans generally run $60 to $120 per 30-day supply. Tier 2 biosimilars like Semglee run $30 to $60. Over a 12-month period, that difference adds up to $360 to $720 in savings for patients who can use the biosimilar.

Medicare Part D and the $35 Cap

The Inflation Reduction Act of 2022 capped out-of-pocket insulin costs at $35 per month for all Medicare Part D enrollees, effective January 1, 2023 5. BCBS Alabama's Medicare Advantage Prescription Drug (MAPD) plans are required to apply this cap. If you are on Medicare and paying more than $35 per month for Lantus, contact BCBS Alabama member services at 1-800-292-8868 to request a correction.

Biosimilar Alternatives Preferred by BCBS Alabama

Three insulin glargine biosimilars are frequently positioned as preferred alternatives to Lantus on BCBS Alabama formularies.

Basaglar (Insulin Glargine-aabc)

Basaglar is manufactured by Eli Lilly and was the first insulin glargine follow-on product approved in the United States (November 2015). It is not designated as interchangeable but is therapeutically equivalent. The 52-week ELEMENT 2 trial (N=756) showed Basaglar achieved HbA1c reduction of 1.29% versus 1.34% for Lantus, a non-significant difference (P<0.001 for non-inferiority) 6. BCBS Alabama plans frequently place Basaglar on Tier 2.

Semglee (Insulin Glargine-yfgn)

Semglee, manufactured by Viatris and Biocon, received FDA interchangeable biosimilar designation in July 2021. That status means Alabama pharmacists can substitute Semglee for Lantus at the pharmacy counter without calling the prescriber. A list price of approximately $147 per vial (versus $292 for Lantus) makes Semglee a common Tier 2 placement on BCBS Alabama plans 2.

Rezvoglar (Insulin Glargine-aglr)

Rezvoglar is Eli Lilly's second insulin glargine biosimilar, launched in January 2023 at a list price of $92 per vial, representing a 78% discount to Lantus list price 7. Some BCBS Alabama plans moved quickly to add Rezvoglar to their preferred tier given this pricing.

Step Therapy: What It Means for Lantus Access

Step therapy requires patients to try one or more preferred drugs before the insurer will cover a non-preferred drug. Many BCBS Alabama plans require a documented trial of Semglee or Basaglar before approving Lantus at the in-network benefit level.

Bypassing Step Therapy

Alabama law (Ala. Code § 27-55-3) allows patients to request a step-therapy exception when:

1. The required drug is contraindicated or causes an adverse reaction in the patient
2. The required drug is expected to be ineffective based on the patient's history
3. The patient has already completed a clinically appropriate course of the step drug and it failed

Your endocrinologist or primary care physician should submit a written exception request citing one of these criteria along with chart notes. Exception requests must be reviewed within 72 hours for urgent cases and within 14 days for standard reviews under Alabama law.

How to Get Prior Authorization Approved for Lantus

A well-prepared PA submission dramatically increases approval odds. Based on published insurer criteria and ADA guidance, a strong PA package includes:

• Current HbA1c lab result (ideally within the past 90 days)
• Fasting glucose log or CGM data showing current glycemic control on Lantus
• Documentation of any adverse events experienced with biosimilar alternatives tried previously
• A letter of medical necessity from the prescriber explaining why the originator product is specifically required
• The ADA's 2024 Standards of Care language supporting individualized insulin selection 4

The insurer's PA decision is binary: approved or denied. If denied, you have the right to an internal appeal followed by an external independent review under the Affordable Care Act.

Internal Appeal

Submit a written internal appeal within 180 days of the denial. Include the same clinical documentation as the original PA plus any peer-reviewed literature on why switching from Lantus to a biosimilar poses specific risks for your patient. A 2021 JAMA Internal Medicine analysis found that patients who submitted written clinical appeals for insulin coverage denials received favorable outcomes in 39% to 54% of cases 8.

External Independent Review

If the internal appeal is denied, request an external review through the Alabama Department of Insurance (ALDOI). External reviewers are independent of BCBS Alabama. Federal rules require the plan to comply with the external reviewer's decision.

Manufacturer Copay Assistance Programs

Even if BCBS Alabama places Lantus on a high cost-share tier, Sanofi offers a Lantus Valyou Savings Program that caps the monthly out-of-pocket cost at $99 for eligible commercially insured patients. Enrollment is available at insulinhelp.sanofi.com. Note that this program cannot be combined with Medicare or Medicaid.

Patients without insurance have access to Sanofi's Insulins Valyou program at $99 per month for up to 10 packs of insulin products. The Eli Lilly Insulin Value Program caps Basaglar at $35 per month 9, making Basaglar the most affordable option for uninsured patients who cannot access Semglee's biosimilar pricing.

What the Clinical Evidence Says About Switching Basal Insulins

Physicians sometimes face pushback when patients are stable on Lantus and insurers demand a switch to a biosimilar. The clinical evidence supports a measured approach.

Glycemic Stability During Transitions

A 2020 observational study published in Diabetes, Obesity and Metabolism (N=1,400) followed patients transitioned from Lantus to Semglee and found mean HbA1c changed by less than 0.1% at 6 months, with no statistically significant change in hypoglycemia frequency 10. This evidence suggests the transition is generally safe.

When Switching May Be Inappropriate

Certain populations may warrant prescriber caution during an insulin switch:

• Patients with hypoglycemia unawareness, where even small pharmacokinetic differences could matter
• Pediatric patients with Type 1 diabetes who have achieved HbA1c below 7.0% on a stable Lantus regimen
• Patients with end-stage renal disease, where insulin clearance is altered and small dose discrepancies compound

The Endocrine Society's 2022 clinical practice guideline on insulin therapy states that "transitions between insulin glargine products should be managed with patient education and glucose monitoring, particularly in high-risk populations" 11.

Reading Your BCBS Alabama Plan Documents

Every BCBS Alabama plan publishes an Evidence of Coverage (EOC) and a drug formulary searchable online. To confirm current Lantus coverage status:

1. Log in to your BCBS Alabama member portal at bcbsal.org
2. Select "Prescription Drug Coverage" and then "Drug Formulary"
3. Search for "insulin glargine" or "Lantus" to view tier, PA requirements, and quantity limits
4. Compare the Lantus entry to Semglee, Basaglar, and Rezvoglar entries side by side

Formularies change annually on January 1. Mid-year changes are possible but require 60-day advance notice to enrollees under ACA rules. If you received a change notice, you have until the end of the current plan year to request a formulary exception or transition fill.

Transition Fills

If Lantus is removed from your plan's formulary mid-year and you are currently taking it, you are entitled to at least a 30-day transition fill at the prior cost-share level. Use that window to pursue a formulary exception with your physician.

Comparing Coverage Across BCBS Alabama Plan Types

BCBS Alabama offers several distinct product lines, and Lantus coverage details differ across them.

Individual and Family Marketplace Plans

ACA marketplace plans sold through healthcare.gov or directly by BCBS Alabama use a formulary that typically places Semglee or Basaglar on Tier 2 and Lantus on Tier 3. The 2024 plan year formulary for the BCBS Alabama Blue Advantage network listed Lantus with PA requirements and a quantity limit of 20 mL per 30 days.

Employer Group Plans (Fully Insured)

Fully insured employer group plans in Alabama are subject to Alabama Department of Insurance oversight. These plans often mirror the individual formulary but may have employer-negotiated custom tiers. Ask your HR department for the Summary Plan Description (SPD) and the attached drug formulary.

Self-Funded Employer Plans

Self-funded (ERISA) plans administered by BCBS Alabama set their own formulary rules and are not subject to Alabama state insurance mandates. PA criteria can be more or less restrictive than fully insured plans. The plan administrator (your employer) controls formulary decisions, not BCBS Alabama directly.

Medicare Advantage Plans

BCBS Alabama Medicare Advantage plans must comply with CMS formulary requirements, including the $35/month insulin cap established by the Inflation Reduction Act. CMS requires all Part D formularies to include at least one insulin product in each insulin category 12. Lantus or its biosimilar equivalents therefore appear on every BCBS Alabama MAPD formulary.

When Lantus Is Not Covered: Practical Next Steps

If BCBS Alabama denies coverage for Lantus and your appeal fails, you still have options.

Switch to the Preferred Biosimilar

Semglee is interchangeable with Lantus. Have your physician write "insulin glargine-yfgn (Semglee), may substitute interchangeable biosimilar" on the prescription, and fill at an in-network pharmacy. Dosing is unit-for-unit identical to Lantus.

Use a Discount Card

GoodRx, Cost Plus Drugs, and similar services negotiate cash prices independent of insurance. Semglee's GoodRx price at Alabama pharmacies runs approximately $68 to $92 per 10 mL vial. This may be lower than your Tier 3 Lantus copay if your deductible has not been met.

Contact BCBS Alabama Member Services

Call 1-800-292-8868 and ask specifically: "Is Lantus covered under my current plan, what tier is it on, and what are the PA criteria?" Request the denial reason in writing if you have already been denied; you need this to file an appeal.

Contact the Alabama Department of Insurance

The ALDOI Consumer Services division handles insurance complaints and can assist with external appeal requests. Their phone number is 1-800-433-3966. Filing a complaint often accelerates resolution with the insurer.